International Consortium on Ehlers–Danlos Syndromes

International Consortium on Ehlers–Danlos Syndromes
Name	International Consortium on Ehlers–Danlos Syndromes
Formation	2015
Type	Non-profit consortium
Region served	International
Leader title	Chair

International Consortium on Ehlers–Danlos Syndromes is a multinational research and clinical collaboration focused on the study, diagnosis, and management of Ehlers–Danlos syndromes and related heritable connective tissue disorders. It unites clinicians, geneticists, patient organizations, and academic institutions to produce consensus diagnostic criteria, coordinate multicenter research, and provide educational resources. The consortium interfaces with international bodies and funding agencies to standardize care and accelerate gene discovery.

History and formation

The consortium originated from meetings among specialists at conferences such as European Society of Human Genetics and American College of Medical Genetics and Genomics, with foundational discussions involving investigators from University of Cambridge, Harvard Medical School, Karolinska Institutet, University of Oxford, and McGill University. Early workshops convened experts who had participated in projects linked to Human Genome Project initiatives and networks like Global Alliance for Genomics and Health. Formal organization followed precedent from collaborative models established by World Health Organization working groups and consortia such as International Rare Diseases Research Consortium, leading to chartering efforts modeled on European Reference Networks.

Mission and objectives

The consortium's mission aligns with aims promoted by entities like National Institutes of Health, European Commission, and Wellcome Trust to improve diagnosis and treatment of rare disorders. Objectives include harmonizing diagnostic criteria in line with standards used by American College of Rheumatology and Royal College of Physicians, promoting genotype–phenotype correlation studies akin to efforts at Stanford University and Cold Spring Harbor Laboratory, and fostering translational research parallel to programs at Massachusetts General Hospital and Mayo Clinic. The group prioritizes patient-centered outcomes similar to initiatives by National Organization for Rare Disorders and European Organisation for Rare Diseases.

Governance and membership

Governance incorporates a steering committee with representation from university hospitals such as Charité – Universitätsmedizin Berlin, Hopital Necker–Enfants Malades, Sheffield Teaching Hospitals, and research centers including Institut Pasteur and Max Planck Society institutes. Membership spans clinical geneticists, molecular biologists, cardiologists, orthopedists, and patient advocates drawn from organizations like Ehlers–Danlos Society, Genetic Alliance, Muscular Dystrophy Association, and national rare disease coalitions in Canada, Australia, France, Germany, and Japan. Advisory roles have involved contributors affiliated with European Molecular Biology Laboratory, Johns Hopkins University, University of Toronto, and University of California, San Francisco.

Research and diagnostic initiatives

The consortium coordinates multicenter studies and registries modeled on platforms used by UK Biobank, ClinGen, and DECIPHER. Projects include exome and genome sequencing campaigns supported by collaborators at Broad Institute, Sanger Institute, and Wellcome Sanger Institute to identify pathogenic variants described in literature from Nature Genetics, American Journal of Human Genetics, and The Lancet. Diagnostic standardization draws on nomenclature frameworks used by OMIM and classification approaches from International Classification of Diseases. The group fosters biomarker discovery through partnerships with laboratories at Dana–Farber Cancer Institute, Vanderbilt University Medical Center, and Scripps Research Institute.

Clinical guidelines and consensus statements

The consortium has produced consensus statements and diagnostic criteria akin to guidance formats from European Society of Cardiology and American Heart Association, with working groups publishing recommendations comparable in scope to documents from British Society for Genetic Medicine and International Society on Thrombosis and Haemostasis. Guidelines address multidisciplinary management involving specialists from Royal College of Surgeons, American Academy of Pediatrics, and European Academy of Neurology, and incorporate data standards interoperable with databases like GenBank and resources maintained by European Bioinformatics Institute.

Education, outreach, and advocacy

Education efforts mirror programs by World Federation of Neurology and professional societies such as American College of Physicians, offering continuing medical education modules and symposiums at meetings like American College of Medical Genetics annual meeting and American Society of Human Genetics. Outreach includes collaboration with patient groups similar to Rare Diseases International to produce patient-facing materials inspired by resources from Mayo Clinic, Cleveland Clinic, and Johns Hopkins Medicine. Advocacy activities engage policymakers and health systems influenced by precedents from National Health Service policy dialogues and campaigns led by European Patient Forum.

Collaborations and funding sources

Collaborators include academic centers such as University College London, Yale School of Medicine, and Peking University Health Science Center, and industry partners in diagnostic development comparable to firms working with Illumina and Thermo Fisher Scientific. Funding sources comprise grants and awards from organizations like National Institutes of Health, European Commission Horizon 2020, Wellcome Trust, private foundations akin to Gates Foundation philanthropic models, and support from patient advocacy foundations patterned after Muscular Dystrophy Association fundraising. Collaborative projects have also received investigator-initiated support through mechanisms used by European Research Council and national research councils in Canada and Germany.

Category:Medical research organizations